Robert H Schenkel

Title: The Innovations of Robert H. Schenkel

Introduction

Robert H. Schenkel is a notable inventor based in Yardley, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 4 patents to his name, Schenkel's work has had a profound impact on vaccine development and disease prevention.

Latest Patents

Schenkel's latest patents include groundbreaking work on antigens and monoclonal antibodies reactive against sporozoites. His first patent describes the use of hybridoma technology to obtain monoclonal antibodies against sporozoites of the Eimeria species. This innovation focuses on specific sporozoite antigens for use as vaccines in the prevention and treatment of coccidiosis. Another significant patent addresses monoclonal antibodies against merozoites of Eimeria tenella, also utilizing hybridoma technology. This patent outlines specific antigens for vaccine development aimed at preventing and treating coccidiosis.

Career Highlights

Robert H. Schenkel has had a distinguished career at American Cyanamid Company, where he has been instrumental in advancing research in immunology and vaccine development. His expertise in hybridoma technology has positioned him as a leader in the field, contributing to the understanding and treatment of various diseases.

Collaborations

Throughout his career, Schenkel has collaborated with esteemed colleagues, including Rosie Bick-Har Wong and Pallaiah Thammana. These partnerships have fostered innovation and have been crucial in the successful development of his patented technologies.

Conclusion

Robert H. Schenkel's contributions to biotechnology and vaccine development are noteworthy. His innovative work with monoclonal antibodies has paved the way for advancements in the prevention and treatment of coccidiosis. Schenkel's legacy as an inventor continues to influence the field and inspire future research.